环巴胺-磷脂共聚物修饰的功能化表阿霉素脂质体及其在异质性乳腺癌中的体外治疗效应

doi:10.5246/jcps.2017.04.026

中国药学(英文版) ›› 2017, Vol. 26 ›› Issue (4): 255-264.DOI: 10.5246/jcps.2017.04.026

环巴胺-磷脂共聚物修饰的功能化表阿霉素脂质体及其在异质性乳腺癌中的体外治疗效应

胡英杰, 张婧莹, 刘磊, 阎妍, 沐黎敏, 白婧, 吴佳栓, 吕万良^*

北京大学医学部药学院天然药物及仿生药物国家重点实验室, 分子药剂学与新释药系统北京市重点实验室, 北京 100191

收稿日期:2017-03-07 修回日期:2017-03-21 出版日期:2017-04-26 发布日期:2017-04-15
通讯作者: Tel.: +86-010-82802683, E-mail: luwl@bjmu.edu.cn
基金资助:
National Basic Research Program of China (973 Program, Grant No. 2013CB932501) and the National Science Foundation of China (Grant No. 81373343, 81673367).

A novel type of functional epirubicin liposomes modified with DSPE-PEG2000-cyclopamine conjugate for eliminating heterogeneous breast cancer cells

Yingjie Hu, Jingying Zhang, Lei Liu, Yan Yan, Limin Mu, Jing Bai, Jiashuan Wu, Wanliang Lu^*

Beijing Key Laboratory of Molecular Pharmaceutics and New Drug System, State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China

Received:2017-03-07 Revised:2017-03-21 Online:2017-04-26 Published:2017-04-15
Contact: Tel.: +86-010-82802683, E-mail: luwl@bjmu.edu.cn
Supported by:
National Basic Research Program of China (973 Program, Grant No. 2013CB932501) and the National Science Foundation of China (Grant No. 81373343, 81673367).

摘要/Abstract

摘要：

普通化学药物治疗难以根除具有耐药性的异质性侧群癌细胞, 因而临床预后效果不理想。异质性侧群癌细胞是导致多药耐药性的主要原因之一, 其耐药性与相关信号通路如Hedgehog (Hh)通路的异常激活有关。环巴胺是一种可阻断Hh通路的化合物, 其联合应用抗癌药可望有效增强对异质性癌细胞的杀伤效果。本研究旨在构建一种可杀伤异质性癌细胞的环巴胺-磷脂共聚物修饰的功能化载药脂质体。研究主要以人乳腺细胞为评价模型。研究结果显示, 通过亲核替换法合成了一种新的功能材料二硬磷脂酰乙醇胺-聚乙二醇-环巴胺(DSPE-PEG₂₀₀₀-cyclopamine)共聚物, 经基质辅助激光解析电离飞行时间质谱(MALDI-TOF-MS)测定, 证实了合成结果; 为了对新制剂进行定量, 建立了表阿霉素高效液相色谱法, 并对方法学进行了有效性验证; 采用新合成的功能性材料对脂质体膜进行修饰, 制备了功能性表阿霉素脂质体, 其粒径为98 nm, 在脂质体中阿霉素的包封率>97%; 采用CD44+/CD24-癌细胞表型免疫标记方法, 对人乳腺癌MCF-7细胞的异质性进行了表征; 与普通表阿霉素脂质体相比, 功能性表阿霉素脂质体显著增强了药物在异质性乳腺癌细胞中的摄取效应以及杀伤效应。因此, 构建的功能性脂质体为异质性乳腺癌细胞的根除提供了一种可选择的新策略。

关键词: 环巴胺共聚物, 表阿霉素, 脂质体, 异质性, 乳腺癌

Abstract:

Common chemotherapy is unable to eliminate the heterogeneous side population of cancer cells (such as cancer stem-likecells), resulting in poor prognosis. The heterogeneity of cancer cells causes an extensive multidrug resistance through the aberrantly active Hedgehog (Hh) signaling pathway. Cyclopamine is a chemical compound that can block Hh signaling pathway, and a combination use of cyclopamine with anticancer drug would be beneficial for killing heterogeneous cancer cells. In the present study, we aimed to develop a kind type of functional drug liposomes for eliminating heterogeneous cancer. The study was performed on human breast cancer cells. A distearoylphosphoethanolamine polyethylene glycol (DSPE-PEG₂₀₀₀)-cyclopamine conjugate was newly synthesized by a nucleophilic substitution reaction, and confirmed by MALDI-TOF mass. An HPLC method was established and validated for qualification of epirubicin. Functional epirubicin liposomes were successful constructed by modifyingwith DSPE-PEG₂₀₀₀-cyclopamine, displaying a particle size in nano-scale (approximately 98 nm) and a high epirubicin encapsulation (>97%). The CD44+/CD24-side population was characterized in defining heterogeneous breast cancer cells. As compared with regular epirubicin liposomes, functional epirubicin liposomes exhibited an evidently enhanced cellular drug uptake and a significant killing effect in overall breast cancer cells. In conclusion, the functional epirubicin liposomes could be a useful drug delivery carrier for eliminating heterogeneous breast cancer cells.

Key words: Cyclopamine conjugate, Epirubin, Liposomes, Heterogeneity, Breast cancer

中图分类号:

R943

Supporting:

胡英杰, 张婧莹, 刘磊, 阎妍, 沐黎敏, 白婧, 吴佳栓, 吕万良. 环巴胺-磷脂共聚物修饰的功能化表阿霉素脂质体及其在异质性乳腺癌中的体外治疗效应[J]. 中国药学(英文版), 2017, 26(4): 255-264.

Yingjie Hu, Jingying Zhang, Lei Liu, Yan Yan, Limin Mu, Jing Bai, Jiashuan Wu, Wanliang Lu. A novel type of functional epirubicin liposomes modified with DSPE-PEG2000-cyclopamine conjugate for eliminating heterogeneous breast cancer cells[J]. Journal of Chinese Pharmaceutical Sciences, 2017, 26(4): 255-264.

参考文献

[1] Shackleton, M.; Quintana, E.; Fearon, E.R.; Morrison, S.J. Cell. 2009, 138, 822-829.

[2] Reya, T.; Morrison, S.J.; Clarke, M.F.; Weissman, I.L. Nature. 2001, 414, 105-111.

[3] Rosen, J.M.; Jordan, C.T. Science. 2009, 234, 1670-1677.

[4] Franqui-Machin, R.; Wendlandt, E.B.; Janz, S.; Zhan, F.; Tricot, G. Oncotarget. 2015, 6, 40496-40506

[5] Ingham, P.W.; McMahon, A.P. Genes Dev. 2001, 15, 3059-3087.

[6] Varjosalo, M.; Taipale, J. Genes Dev. 2008, 22, 2454- 2472.

[7] Merchant, A.A.; Matsui, W. Clin. Cancer Res. 2010, 16, 3130-3140.

[8] Clement, V.; Sanchez, P.; de Tribolet, N.; Radovanovic, I.; Altaba, A. Curr. Biol. 2007, 17, 165-172.

[9] Bar, E.E.; Chaudhry, A.; Lin, A.; Fan, X.; Schreck, K.; Matsui, W.; Piccirillo, S.; Vescovi, A.L.; DiMeco, F.; Olivi, A.; Eberhart, C.G. Stem Cells. 2007, 25, 2524- 2533.

[10] Liu, S.; Dontu, G.; Mantle, I.D.; Patel, S.; Ahn, N.S.; Jackson, K.W.; Suri, P.; Wicha, M.S. Cancer Res. 2006, 66, 6063-6071.

[11] Dierks, C.; Beigi, R.; Guo, G.R.; Zirlik, K.; Stegert, M.R.; Manley, P.; Trussell, C.; Schmitt-Graeff, A.; Landwerlin, K.; Veelken, H.; Warmuth, M. Cancer Cell. 2008, 14, 238-249.

[12] Zhao, C.; Chen, A.; Jamieson, C.H.; Fereshteh, M.; Abrahamsson, A.; Blum, J.; Kwon, H.Y.; Kim, J.; Chute, J.P.; Rizzieri, D.; Munchhof, M.; VanArsdale, T.; Beachy, P.A.; Reya, T. Nature. 2009, 458, 776-779.

[13] Feldmann, G.; Dhara, S.; Fendrich, V.; Bedja, D.; Beaty, R.; Mullendore, M.; Karikari, C.; Alvarez, H.; Iacobuzio-Donahue, C.; Jimeno, A.; Gabrielson, K.L.; Matsui, W.; Maitra A. Cancer Res. 2007, 67, 2187- 2196.

[14] Karhadkar, S.S.; Bova, G.S.; Abdallah, N.; Dhara, S.; Gardner, D.; Maitra, A.; Isaacs, J.T.; Berman, D.M.; Beachy, P.A. Nature. 2004, 431, 707-712.

[15] Binns, W.; Keeler, R.F.; Balls, L.D. Clin. Toxicol. 1972, 5, 245-261.

[16] Taipale, J.; Chen, J.K.; Cooper, M.K.; Wang, B.; Mann, R.K.; Milenkovic, L.; Scott, M.P.; Beachy, P.A. Nature. 2000, 406, 1005-1009.

[17] Scales, S.J.; De Sauvage, F.J. Trends Pharmacol. Sci. 2009, 30, 303-312.

[18] Lee, J.E.; Bae, S.H.; Choi, J.Y.; Yoon, S.K.; You, Y.K.; Lee, M.A. World. J. Gastroenterol. 2014, 20, 235-241.

[19] Ju, R.J.; Li, X.T.; Shi, J.F.; Li, X.Y.; Sun, M.G.; Zeng, F.; Zhou, J.; Liu, L.; Zhang, C.X.; Zhao, W.Y.; Lu, W.L. Biomaterials. 2014, 35, 7610-7621

[20] Woodle, M.C.; Lasic, D.D. Biochim. Biophys. Acta. 1992, 1113, 171-199.

[21] Liu, Y.; Lu, W.L.; Guo, J.; Du, J.; Li, T.; Wu, J.W.; Wang, G.L.; Wang, J.C.; Zhang, X.; Zhang, Q. J. Control Release. 2008, 129, 18-25.

[22] Chen, J.K.; Taipale, J.; Cooper, M.K.; Beachy. P.A. Genes Dev. 2002, 16, 2743-2748.

环巴胺-磷脂共聚物修饰的功能化表阿霉素脂质体及其在异质性乳腺癌中的体外治疗效应

A novel type of functional epirubicin liposomes modified with DSPE-PEG2000-cyclopamine conjugate for eliminating heterogeneous breast cancer cells

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	朱文涛, 洪望龙, 郑淼淼, 马国强, 沈爱宗. 帕博利珠单抗联合化疗一线治疗晚期三阴性乳腺癌的成本-效果分析[J]. 中国药学(英文版), 2023, 32(7): 587-597.
[2]	彭词艳, 陈景, 李斯妮, 李健和, 彭六保. 哌柏西利联用来曲唑对比多西他赛联用表柔比星一线治疗晚期乳腺癌的循证药物经济学评价[J]. 中国药学(英文版), 2023, 32(3): 214-222.
[3]	董建伟, 李雪娇, 杨晨, 张艳清, 周慧芳, 李亚丽. 米曲霉和团青霉固态发酵提高火棘果抗氧化活性、总酚和总黄酮含量[J]. 中国药学(英文版), 2022, 31(6): 452-460.
[4]	刘雅婕, 王雨, 李佳佳, 许晓庆, 李馨儒. 载阿霉素-芦米司匹多囊脂质体的制备及体内外评价[J]. 中国药学(英文版), 2021, 30(9): 736-742.
[5]	王惊雷, 宋柯, 潘昊, 刘洋, 王大壮, 陈立江. 纳米药物在肿瘤治疗中的现状和挑战[J]. 中国药学(英文版), 2021, 30(5): 359-380.
[6]	雍灵, 姚烨, 韩梦仪, 严晓雪, 姚庆宇, 郭昱辰, 薛钧升, 陈国术, 周田彦. QAP21抑制转移性乳腺癌细胞的干性和运动能力[J]. 中国药学(英文版), 2021, 30(4): 289-305.
[7]	韩梦仪, 雍灵, 郭昱辰, 严晓雪, 陈国术, 孔大明, 周田彦. QAP14抑制4T1乳腺癌肺转移的群体药效学随机模型[J]. 中国药学(英文版), 2021, 30(10): 794-805.
[8]	邓华, 高超, 位灯国, 刘思思. 基于端粒G-四链体结构的三阴性乳腺癌细胞抑制剂的虚拟筛选[J]. 中国药学(英文版), 2020, 29(6): 383-389.
[9]	雷萌, 王雪源, 苗航, 王佳, 沙思佳, 朱姜, 朱永强. 叶酸靶向聚合物纳米粒共传输紫杉醇和吉西他滨用于乳腺癌的治疗[J]. 中国药学(英文版), 2020, 29(10): 701-710.
[10]	杨亮, 姚烨, 冯瑶瑶, 卢炜, 周田彦. 多巴胺D1激动剂治疗乳腺癌肺转移的药效动力学模型[J]. 中国药学(英文版), 2020, 29(1): 45-54.
[11]	王雪玲, 梁艳琴, 张元, 何冰, 代文兵, 张华, 王学清, 张强. cRGD-DOX自组装纳米粒与贝伐珠单抗联合治疗乳腺癌[J]. 中国药学(英文版), 2019, 28(9): 627-640.
[12]	王佳星, 王雨, 牟家慧, 魏潇萌, 殷梦雅, 刘雅婕, 李佳佳, 李馨儒. 脂质体对细菌外膜囊泡的修饰及其体外评价[J]. 中国药学(英文版), 2019, 28(8): 571-578.
[13]	杜祎甜, 张泸, 詹颖, 柴新宇, 李锴森, 齐宪荣. 制备干扰素脂质体使小胶质细胞维持M1表型[J]. 中国药学(英文版), 2019, 28(7): 476-483.
[14]	邓博, 崔巍, 马爽, 刘晓娜, 张展, 闫百艺, 陈坤, 谢英. RVGP修饰脑靶向脂质体合理构建的分子基础[J]. 中国药学(英文版), 2019, 28(7): 484-501.
[15]	郝艳丽, 钟婷, 杜若, 张华, 刘碧林, 张烜. 包载共轭亚油酸-紫杉醇的iRGD修饰的含溶血磷脂的温敏脂质体的细胞摄取和抗肿瘤药效[J]. 中国药学(英文版), 2019, 28(2): 121-133.